Zafgen Inc. (ZFGN) 39.90 $ZFGN
3 Bursting Biotech Stocks -- 1 To Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 9:51AM CDT
The biotech industry is notorious for its pop-and-drop nature, but it also offers opportunities for risk-tolerant investors. For instance, these three companies' stock prices have tumbled, and one could be worth buying. In the following slideshow I...
ZFGN: 39.90 (-0.62), OVAS: 30.40 (-0.55), XLRN: 33.29 (-0.95)
The Best Stock to Invest in Obesity Drugs
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 12, 1:03PM CDT
Considering the limited number of obesity drugs, it seems easiest to pick the best stock in the field by process of elimination. Company Drug FDA Approved? Roche Xenical Yes VIVUS ...
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Zafgen (ZFGN) Crumbles: Stock Falls by 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:53AM CDT
Zafgen saw a big move last session, as the company’s shares fell by 8%. This reverses the recent trend for ZFGN as the stock is now up around 10% in the past one-month time frame.
LCI: 67.40 (unch), ZFGN: 39.90 (-0.62)
Vivus, Arena, Or Orexigen - Which Will Win The Anti-Obesity Market Share Race?
Spencer Osborne - at Seeking Alpha - Mon Mar 23, 2:57PM CDT
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Zafgen's (ZFGN) CEO Tom Hughes on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 20, 6:26PM CDT
ZFGN: 39.90 (-0.62)
Zafgen Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 4:58AM CDT
ZFGN: 39.90 (-0.62)
Zafgen beats by $0.36
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 3:09PM CDT
ZFGN: 39.90 (-0.62)
Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Mar 19, 3:00PM CDT
Quarter and Full Year Highlighted by Further Progress in Advancing Beloranib Clinical Development Program
ZFGN: 39.90 (-0.62)
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Mar 12, 4:38PM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it will host a conference call on Thursday, March 19, 2015 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and the full year ended December 31, 2014.
ZFGN: 39.90 (-0.62)
5 Health Care Stocks to Trade for Breakout Gains in March
at The Street - Tue Mar 03, 6:08AM CST
Here's a technical look at five of the best breakout setups in the health care sector right now.
ZFGN: 39.90 (-0.62), DXCM: 69.43 (-1.13), EW: 138.33 (-3.59), GSK: 46.59 (+0.28), NVDQ: 11.86 (-0.25)
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Pipeline Review 2015 - 12 Companies & 20 Drug Profiles
M2 - Mon Mar 02, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/ngqxpk/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015" report to their offering. Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Conatus Pharmaceuticals Inc. - Daewoong Pharmaceutical Co., Ltd. - Galmed International Ltd. - Kyorin Pharmaceutical Co., Ltd. - Metabolic Solutions Development Company, LLC - Novartis AG - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. - TCM Biotech International Corp - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited - Zafgen Inc. Drug Profiles - Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Aramchol - cenicriviroc - cysteamine DR - DWP-10292 - emricasan - MAT-8800 - MB-12066 - methazolamide - MN-002 - MSDC-0602 - oltipraz - pradigastat sodium - Px-102 - Px-103 - Px-104 - Small Molecules to Activate AMPK for Fatty Liver Disease - TCM-606F - VVP-100-X - ZGN-839 For more information visit http://www.researchandmarkets.com/research/ng..._alcoholic
ZFGN: 39.90 (-0.62), RPTP: 10.81 (+0.10), CNAT: 6.66 (-0.15), TBRA: (), NVS: 104.28 (-1.22)
Zafgen to Present at the 2015 RBC Capital Markets Conference
GlobeNewswire - Wed Feb 18, 3:03PM CST
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, is scheduled to present at the 2015 RBC Capital Markets Conference on Wednesday, February 25, 2015 at 2:35 PM ET. A live audio webcast of the presentation will be available on Zafgen's website, www.zafgen.com.
ZFGN: 39.90 (-0.62)
Zafgen Offers Hope For The Obese
ARK Investment Management - Seeking Alpha - Tue Feb 10, 12:12PM CST
by James Bannon, ARK Analyst It is no secret that obesity is linked to health risks. Obesity is associated with a higher risk of cancer, diabetes, heart disease, and stroke , as well as the psychological effects from discrimination and the...
ZFGN: 39.90 (-0.62)
Zafgen to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:10PM CST
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas Hughes, Ph.D., Chief Executive Officer, is scheduled to present a company overview at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 3:30pm ET at the Waldorf Astoria in New York. A live audio webcast of the presentation will be available on Zafgen's website at www.zafgen.com.
ZFGN: 39.90 (-0.62)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.90 (-0.62), GPRO: 44.73 (-1.35), CLDN: 13.68 (-0.26), ZEN: 23.42 (-0.40), ASPX: 100.88 (-0.01), TNET: 35.20 (-0.14), NVRO: 53.37 (-0.22), OCUL: 25.36 (-1.12), RDUS: 41.01 (-0.95), ALDR: 25.10 (-0.25), IRMD: 15.74 (-0.06), KITE: 60.58 (-0.35), TUBE: 15.45 (-0.07), VBLT: 4.23 (+0.07)
Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), ETRM: 1.15 (+0.01), HWAY: 17.61 (-1.89), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares
GlobeNewswire - Wed Jan 28, 3:09PM CST
Zafgen, Inc. (Nasdaq:ZFGN) today announced the closing of its underwritten public offering of 3,942,200 shares of its common stock at a price of $35.00 per share before underwriting discounts, which includes the full-exercise of the underwriters' option to purchase an additional 514,200 shares of common stock at the public offering price, less the underwriting discounts.
ZFGN: 39.90 (-0.62)
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), ETRM: 1.15 (+0.01), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), TEVA: 64.41 (+1.16), GSK: 46.59 (+0.28), SNY: 51.75 (-0.01), ARNA: 4.49 (+0.05)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 8:11AM CST
ZFGN: 39.90 (-0.62), PWE: 2.41 (-0.03), VGGL: 2.55 (-0.10), VTAE: 14.05 (+0.12), ETFC: 28.17 (-0.02), DWA: 26.00 (+0.25), FXCM: 2.08 (-0.03), NBG: 1.23 (+0.06), MT: 10.49 (+0.41), UPS: 98.10 (-0.12), LF: 2.28 (-0.05), ARRY: 7.19 (-0.12), INFN: 20.15 (+0.81)
3 Bursting Biotech Stocks -- 1 To Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 9:51AM CDT
The biotech industry is notorious for its pop-and-drop nature, but it also offers opportunities for risk-tolerant investors. For instance, these three companies' stock prices have tumbled, and one could be worth buying. In the following slideshow I...
ZFGN: 39.90 (-0.62), OVAS: 30.40 (-0.55), XLRN: 33.29 (-0.95)
The Best Stock to Invest in Obesity Drugs
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 12, 1:03PM CDT
Considering the limited number of obesity drugs, it seems easiest to pick the best stock in the field by process of elimination. Company Drug FDA Approved? Roche Xenical Yes VIVUS ...
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Zafgen (ZFGN) Crumbles: Stock Falls by 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:53AM CDT
Zafgen saw a big move last session, as the company’s shares fell by 8%. This reverses the recent trend for ZFGN as the stock is now up around 10% in the past one-month time frame.
LCI: 67.40 (unch), ZFGN: 39.90 (-0.62)
Vivus, Arena, Or Orexigen - Which Will Win The Anti-Obesity Market Share Race?
Spencer Osborne - at Seeking Alpha - Mon Mar 23, 2:57PM CDT
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Zafgen's (ZFGN) CEO Tom Hughes on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 20, 6:26PM CDT
ZFGN: 39.90 (-0.62)
Zafgen Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 4:58AM CDT
ZFGN: 39.90 (-0.62)
Zafgen beats by $0.36
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 3:09PM CDT
ZFGN: 39.90 (-0.62)
Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Mar 19, 3:00PM CDT
Quarter and Full Year Highlighted by Further Progress in Advancing Beloranib Clinical Development Program
ZFGN: 39.90 (-0.62)
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Mar 12, 4:38PM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it will host a conference call on Thursday, March 19, 2015 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and the full year ended December 31, 2014.
ZFGN: 39.90 (-0.62)
5 Health Care Stocks to Trade for Breakout Gains in March
at The Street - Tue Mar 03, 6:08AM CST
Here's a technical look at five of the best breakout setups in the health care sector right now.
ZFGN: 39.90 (-0.62), DXCM: 69.43 (-1.13), EW: 138.33 (-3.59), GSK: 46.59 (+0.28), NVDQ: 11.86 (-0.25)
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Pipeline Review 2015 - 12 Companies & 20 Drug Profiles
M2 - Mon Mar 02, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/ngqxpk/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015" report to their offering. Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Conatus Pharmaceuticals Inc. - Daewoong Pharmaceutical Co., Ltd. - Galmed International Ltd. - Kyorin Pharmaceutical Co., Ltd. - Metabolic Solutions Development Company, LLC - Novartis AG - Phenex Pharmaceuticals AG - Raptor Pharmaceuticals Corp. - TCM Biotech International Corp - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited - Zafgen Inc. Drug Profiles - Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Aramchol - cenicriviroc - cysteamine DR - DWP-10292 - emricasan - MAT-8800 - MB-12066 - methazolamide - MN-002 - MSDC-0602 - oltipraz - pradigastat sodium - Px-102 - Px-103 - Px-104 - Small Molecules to Activate AMPK for Fatty Liver Disease - TCM-606F - VVP-100-X - ZGN-839 For more information visit http://www.researchandmarkets.com/research/ng..._alcoholic
ZFGN: 39.90 (-0.62), RPTP: 10.81 (+0.10), CNAT: 6.66 (-0.15), TBRA: (), NVS: 104.28 (-1.22)
Zafgen to Present at the 2015 RBC Capital Markets Conference
GlobeNewswire - Wed Feb 18, 3:03PM CST
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, is scheduled to present at the 2015 RBC Capital Markets Conference on Wednesday, February 25, 2015 at 2:35 PM ET. A live audio webcast of the presentation will be available on Zafgen's website, www.zafgen.com.
ZFGN: 39.90 (-0.62)
Zafgen Offers Hope For The Obese
ARK Investment Management - Seeking Alpha - Tue Feb 10, 12:12PM CST
by James Bannon, ARK Analyst It is no secret that obesity is linked to health risks. Obesity is associated with a higher risk of cancer, diabetes, heart disease, and stroke , as well as the psychological effects from discrimination and the...
ZFGN: 39.90 (-0.62)
Zafgen to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:10PM CST
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas Hughes, Ph.D., Chief Executive Officer, is scheduled to present a company overview at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 3:30pm ET at the Waldorf Astoria in New York. A live audio webcast of the presentation will be available on Zafgen's website at www.zafgen.com.
ZFGN: 39.90 (-0.62)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.90 (-0.62), GPRO: 44.73 (-1.35), CLDN: 13.68 (-0.26), ZEN: 23.42 (-0.40), ASPX: 100.88 (-0.01), TNET: 35.20 (-0.14), NVRO: 53.37 (-0.22), OCUL: 25.36 (-1.12), RDUS: 41.01 (-0.95), ALDR: 25.10 (-0.25), IRMD: 15.74 (-0.06), KITE: 60.58 (-0.35), TUBE: 15.45 (-0.07), VBLT: 4.23 (+0.07)
Despite the CDC's Best Efforts, This Disease Just Hit Record Levels
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 02, 8:12AM CST
Source: Flickr user Next TwentyEight. Although cancer and heart disease may garner a significant portion of researchers' attention, obesity is a growing problem . According to estimates from the Centers for Disease Control and Prevention, more...
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), ETRM: 1.15 (+0.01), HWAY: 17.61 (-1.89), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares
GlobeNewswire - Wed Jan 28, 3:09PM CST
Zafgen, Inc. (Nasdaq:ZFGN) today announced the closing of its underwritten public offering of 3,942,200 shares of its common stock at a price of $35.00 per share before underwriting discounts, which includes the full-exercise of the underwriters' option to purchase an additional 514,200 shares of common stock at the public offering price, less the underwriting discounts.
ZFGN: 39.90 (-0.62)
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?
Spencer Osborne - at Seeking Alpha - Wed Jan 28, 10:49AM CST
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), ETRM: 1.15 (+0.01), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
What Investors Should Do About Imminent Obesity Drug Approvals In Europe
Rx Stocks - at Seeking Alpha - Tue Jan 27, 7:38AM CST
ZFGN: 39.90 (-0.62), OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), TEVA: 64.41 (+1.16), GSK: 46.59 (+0.28), SNY: 51.75 (-0.01), ARNA: 4.49 (+0.05)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 8:11AM CST
ZFGN: 39.90 (-0.62), PWE: 2.41 (-0.03), VGGL: 2.55 (-0.10), VTAE: 14.05 (+0.12), ETFC: 28.17 (-0.02), DWA: 26.00 (+0.25), FXCM: 2.08 (-0.03), NBG: 1.23 (+0.06), MT: 10.49 (+0.41), UPS: 98.10 (-0.12), LF: 2.28 (-0.05), ARRY: 7.19 (-0.12), INFN: 20.15 (+0.81)
